1型糖尿病预防与异质性的观点
本文讨论异质性和偶然性对1型糖尿病预防试验证据解读和未来试验设计的影响。以TN10 teplizumab试验为例模拟显示,风险异质性不等于治疗效应异质性,识别效应修饰因素所需样本量可能约为确定总体疗效所需样本量的四倍。2×2析因设计可提高试验效率,而针对普通人群婴儿的多价抗病毒疫苗预防试验可能需要超过50,000名参与者。
要点
- 风险异质性不等同于治疗效应异质性,识别效应修饰因素需更大样本量。
- 2×2析因设计可提高预防试验效率,同时评估两种干预。
- 普通人群婴儿多价抗病毒疫苗试验可能需超过50,000名参与者,启动前需稳健安全性数据。
核心结论
- 1型糖尿病预防仍面临重大挑战,但持续努力正使目标更接近。
- 风险异质性不等同于治疗效应异质性,识别治疗效应异质性可能需要更大样本量。
- 当前预防策略靶向高危个体,减少所需参与者数量但增加识别成本。
研究设计与样本
- 本文为观点性文章,使用模拟方法说明以时间至事件为终点的预防试验中疗效估计的不确定性,以TN10 teplizumab试验为例。
- 模拟涉及多种测试策略下探索性研究的统计功效,以及针对1型糖尿病内型的策略。
主要发现
- 在某些情景下,稳健识别治疗效应异质性所需样本量约为确定总体疗效所需样本量的四倍。
- 2×2析因设计研究两种治疗选择可提高预防试验效率。
- 针对普通人群婴儿的多价抗病毒疫苗预防试验可能需超过50,000名参与者,取决于情况和假设。
关键数值与推荐
- 识别治疗效应异质性所需样本量约为总体疗效所需样本量的四倍(特定情景下)。
- 普通人群婴儿多价抗病毒疫苗试验可能需超过50,000名参与者。
临床怎么用
- 解读预防试验证据时应考虑异质性和偶然性的影响。
- 规划未来试验时可考虑2×2析因设计以提高效率。
- 应致力于发现可操作的非内型特异性病因因素。
局限性
- 本文为观点性文章,基于模拟而非实证研究。
- 主观判断和实用主义会影响预防试验是否以及如何规划。
- 针对普通人群婴儿的疫苗试验在启动前需要稳健的安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preventing type 1 diabetes remains a significant challenge but ongoing efforts are bringing us closer to this goal. This article discusses some implications of heterogeneity and chance in relation to prevention of type 1 diabetes, particularly regarding interpretation of evidence and planning of future trials. Using simulations, I illustrate uncertainties in efficacy estimates in prevention trials with time-to-event endpoints, using the TN10 teplizumab trial as an example. I emphasise that risk heterogeneity does not equate to treatment effect heterogeneity. When factors modifying efficacy are taken into account, robust identification of treatment effect heterogeneity may require sample sizes approximately four times larger than those needed to determine overall efficacy in certain scenarios. Efficiency of prevention trials can be increased using 2 × 2 factorial designs investigating two treatment options. I also simulate statistical power in exploratory studies involving multiple testing with different strategies for handling potential type 1 diabetes endotypes. If endotypes are defined as subtypes of type 1 diabetes-related phenotypes with at least partially unique risk factors, it becomes clear that we should aim to discover actionable aetiological factors that are not endotype-specific. Subjective judgements and pragmatism will influence whether and how a prevention trial is planned. Current approaches target high-risk individuals, which reduces the required number of trial participants but increases the cost of identifying trial participants. A prevention trial targeting infants in the general population with a multivalent antiviral vaccine will likely need over 50,000 participants, depending on circumstances and assumptions. While such a trial is conceivable, it would demand robust safety data before initiation.
引用
- Stene LC. Perspectives on prevention of type 1 diabetes and heterogeneities. Diabetologia. 2025. PMID: 40768045. doi:10.1007/s00125-025-06512-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。